Document is current
Any future updates will be listed below
-
Authors
Flouri, Irini D.
Repa, Argyro
Avgoustidis, Nestor
Pitsigavdaki, Sofia
Kalogiannaki, Eleni
Kalligianni-Sofikiti, Konstantina
Emmanouilidou, Evgenia
Marolachaki, Eleni
Bertsias, George
Sidiropoulos, Prodromos
-
Funding
Funding for this research was provided by:
Novartis Hellas (723/7-6-22)
- License Information
-
More Information
Article History
Received: 27 June 2025
Accepted: 28 September 2025
First Online: 3 November 2025
Declarations
:
: Ethical approval for this study was obtained from the local Institutional Review Board (ref. number 1348/09.03.2022). Written informed consent was provided by all patients according to the Declaration of Helsinki.
: Not applicable.
: PS has received consulting and speaking fees from AbbVie, Eli Lilly, Novartis, Pfizer, Sobi and UCB and grants/research support from AbbVie, Pfizer, Eli Lilly, Novartis, UCB, Merck Sharp & Dohme, Roche, Amgen, GSK, Boeringer-Ingelheim, AstraZeneca, Janssen, Sandoz and Biocon. GB has received consulting and speaking fees from AstraZeneca, Bristol Myers Squibb, GSK, Novartis, Otsuka, Eli Lilly, Abbvie, UCB and grants/research support from Merck Sharp & Dohme and AstraZeneca. All other authors have no competing interests.
